v3.26.1
Segment Reporting - Schedule of Research and Development Expenses (Details) - Research and Development Activities Segment - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
External clinical development expenses $ 1,712,599 $ 11,723,402 $ 7,041,837 $ 16,625,769
Personnel related and stock-based compensation 1,644,315 1,408,024 3,357,113 2,745,773
Other research and development expenses 585,018 1,206,327 1,478,662 2,163,468
Total research and development expenses 3,941,932 14,337,753 11,877,612 21,535,010
SBI-100        
Segment Reporting [Line Items]        
External clinical development expenses 0 0 0 2,241
nimacimab        
Segment Reporting [Line Items]        
External clinical development expenses $ 1,712,599 $ 11,723,402 $ 7,041,837 $ 16,623,528